Advancements in drug formulations, synergistic combinations with other antidiabetic medications, and improved safety profiles are poised to drive market expansion during the forecast period
Furthermore, these drugs induce benefits in terms of post-prandial hyperglycemia control in addition to positive effects on -cell function and possible -cell preservation [13]
Beyond weight loss, retatrutide produces significant metabolic benefits: 30% reduction in triglycerides, 8% increase in HDL cholesterol, 7.4 mmHg decrease in systolic blood pressure, 50% reduction in liver fat, and improved glycemic control (HbA1c reduction of 0.4% even in non-diabetics)
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications increasingly prescribed in the UK for type 2 diabetes management and, in specific cases, for weight management in adults with obesity
Schaeffer Center for Health Policy & Economics